Carestream Honored as one of 'Best Healthcare Brands' in India
The award recognizes Carestream's commitment to delivering innovative, reliable, and patient-centric healthcare solutions.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Toronto Star
25 minutes ago
- Toronto Star
Quantum Biopharma Reports Strong Second Quarter with Increased Current and Total Assets, Conversion of all Debentures into Equity, Continued Exclusion of Going Concern, Tripling of Share Price during Quarter, over $500,000 USD Gain in Crypto Assets as of date of filing, and Near Elimination of Debt
TORONTO, Aug. 07, 2025 (GLOBE NEWSWIRE) — Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ('Quantum BioPharma' or the 'Company'), is pleased to announce its financial and operational results for the second quarter ending June 30, 2025. Overall, the Company is in a strong position having increased its current and total assets, compared to the previous quarter; eliminated the entire debt liability associated with debentures issued in Q4 2024 and Q1 2025 by converting all debentures into equity; maintained its 'no going concern' status; seen greater than $500,000 USD appreciation in the value of its cryptocurrency reserves as of date of filing; and seen its stock price almost tripled from $7.71 USD at Q1 close March 31, 2025 to $20.25 USD at Q2 close June 30, 2025. Management believes that there is sufficient cash on hand to maintain basic operations beyond March 2027.
Toronto Star
25 minutes ago
- Toronto Star
Xali Gold Trading Halt
VANCOUVER, British Columbia, Aug. 07, 2025 (GLOBE NEWSWIRE) — Xali Gold Corp. (TSXV: XGC) ('Xali Gold' or 'the Company') advises that the British Columbia Securities Commission has notified the Company that it has issued a cease trade order ('FFCTO') under Multilateral Instrument 11-103 – Failure-to-File Cease Trade Orders in Multiple Jurisdictions for the Company. The FFCTO was issued as a result of the Company's delay in filing its audited annual financial statements, accompanying management discussion and analysis, and CEO and CFO certifications for the financial year ended March 31, 2025 (the 'Annual Filings') in accordance with applicable Canadian securities laws. The FFTCO prohibits any trading, whether direct or indirect, in respect of each security of the Company in each jurisdiction in Canada until such time as the Company is able to complete the filing of the Annual Filings.
Toronto Star
25 minutes ago
- Toronto Star
XORTX Provides Corporate Update and Planned Activities for 2025 / 2026
CALGARY, Alberta, Aug. 07, 2025 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. ('XORTX' or the 'Company') (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, is pleased to provide a comprehensive update on its 2025 progress and strategic goals for 2026. The first half of 2025 has been marked by intense focus and significant advancement, solidifying a robust plan to accelerate the lead gout program towards a NDA filing, aiming to propel technology toward revenue generation and foster substantial shareholder value.
